Steinman L, Mantegazza R
Department of Genetics, Stanford University School of Medicine, California 94305.
FASEB J. 1990 Jul;4(10):2726-31. doi: 10.1096/fasebj.4.10.2197152.
Myasthenia gravis is an autoimmune disease resulting from a breakdown in T and B cell tolerance to acetylcholine receptor (AChR). Autoantibodies to AChR mediate the disease. Recent advances in experimental immunotherapy of autoimmune disease provide several possibilities for specific intervention in this well-characterized condition.
重症肌无力是一种自身免疫性疾病，由T细胞和B细胞对乙酰胆碱受体（AChR）的耐受性破坏所致。针对AChR的自身抗体介导了该疾病。自身免疫性疾病实验性免疫疗法的最新进展为针对这种特征明确的病症进行特异性干预提供了多种可能性。
Zotero 插件